Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Access to Data and Biospecimens, 2014
    CRP40 Expression as a Biomarker of Parkinson’s Disease

    Objective/Rationale:            
    Alterations in HSPA9 gene expression has been described in Parkinson’s disease (PD). Ongoing studies suggest the expression of CRP40, a gene product of HSPA9, in the...

  • Research Grant, 2014
    CD163+ Macrophages as Tools for Neuroinflammatory Modulation in Parkinson’s Disease Supplement

    Promising Outcomes of Original Grant:
    Our fundamental hypothesis was that modulation of blood CD163+ macrophages using nanoparticles loaded with anti-inflammatory drugs could protect neurons in the...

  • Linked Efforts to Accelerate Parkinson’s Solutions, 2014
    Alpha-Synuclein Assay Standardization LEAPS

    Study Rationale:
    The presence of alpha-synuclein protein in biofluids such as blood, cerebrospinal fluid and saliva has been reported by multiple scientists using a variety of analytical techniques...

  • Target Validation, 2014
    Alpha-Galactosidase A as a Therapeutic Target for Parkinson’s Disease

    Objective/Rationale:             
    Alpha Galactosidase A (alpha-Gal A) is an enzyme that recycles lipids in cells. Our preliminary data demonstrates alpha-Gal A deficiency in brains of Parkinson’s...

  • Research Grant, 2014
    Saliva Alpha-synuclein Levels in LRRK2 Mutation Carriers

    Study Rationale:       
    Biomarkers are needed to assist with the diagnosis of Parkinson’s disease (PD) and with monitoring its progression. Decreased levels of alpha-synuclein in cerebrospinal fluid...

  • Therapeutic Pipeline Program, 2014
    Optimization of Dopamine D4 Antagonists for the Treatment of Levodopa-induced Dyskinesia

    Study Rationale:                   
    Levodopa-induced dyskinesia is a major dose-limiting effect associated with long-term treatment of Parkinson’s disease (PD). There are no effective treatments for...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.